162 related articles for article (PubMed ID: 34714596)
41. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Nangaku M; Kondo K; Takabe S; Ueta K; Kaneko G; Otsuka M; Kawaguchi Y; Komatsu Y
Ther Apher Dial; 2021 Oct; 25(5):642-653. PubMed ID: 33283981
[TBL] [Abstract][Full Text] [Related]
42. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
[TBL] [Abstract][Full Text] [Related]
43. HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.
Patel VJ; Joharapurkar A; Kshirsagar SG; Patel MS; Savsani HH; Dodiya HS; Rakhasiya MH; Kajavadara C; Valani D; Jain MR
Toxicol Appl Pharmacol; 2024 Feb; 483():116832. PubMed ID: 38266872
[TBL] [Abstract][Full Text] [Related]
44. Vadadustat: First Approval.
Markham A
Drugs; 2020 Sep; 80(13):1365-1371. PubMed ID: 32852744
[TBL] [Abstract][Full Text] [Related]
45. Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents.
Kowalski H; Hoivik D; Rabinowitz M
Toxicol Pathol; 2023 Jan; 51(1-2):56-60. PubMed ID: 37158494
[TBL] [Abstract][Full Text] [Related]
46. Investigation of in vitro generated metabolites of GLPG0492 using equine liver microsomes for doping control.
Karatt TK; Sathiq MA; Laya S; Philip M; Karakka Kal AK; Subhahar MB
Drug Test Anal; 2023 Jun; 15(6):605-628. PubMed ID: 36762383
[TBL] [Abstract][Full Text] [Related]
47. Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero-Test bile string.
Tai G; Xia F; Chen C; Pereira A; Pirhalla J; Miao X; Young G; Beaumont C; Chen L
Pharmacol Res Perspect; 2023 Dec; 11(6):e1145. PubMed ID: 37885335
[TBL] [Abstract][Full Text] [Related]
48. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury.
Billin AN; Honeycutt SE; McDougal AV; Kerr JP; Chen Z; Freudenberg JM; Rajpal DK; Luo G; Kramer HF; Geske RS; Fang F; Yao B; Clark RV; Lepore J; Cobitz A; Miller R; Nosaka K; Hinken AC; Russell AJ
Skelet Muscle; 2018 Nov; 8(1):35. PubMed ID: 30424786
[TBL] [Abstract][Full Text] [Related]
49. Daprodustat prevents cyclosporine-A-mediated anemia and peritubular capillary loss.
Labes R; Brinkmann L; Kulow VA; Roegner K; Mathia S; Balcerek B; Persson PB; Rosenberger C; Fähling M
Kidney Int; 2022 Oct; 102(4):750-765. PubMed ID: 35643373
[TBL] [Abstract][Full Text] [Related]
50. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control.
Ishii H; Shibuya M; So YM; Wong JKY; Ho ENM; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
Drug Test Anal; 2022 Feb; 14(2):233-251. PubMed ID: 34612014
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
[TBL] [Abstract][Full Text] [Related]
53. A validated method for the quantification of IOX-2, a potent prolyl hydroxylase inhibitor in equine urine and plasma using liquid chromatography-high-resolution mass spectrometry.
Mikhail E; Siccardi E; Bawazir A; Rajesh A; Prathyush S; Al Wazani DMK; Sabeek M; John T
Drug Test Anal; 2021 Jun; 13(6):1178-1190. PubMed ID: 33533201
[TBL] [Abstract][Full Text] [Related]
54. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
Haase VH
Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
Jain M; Joharapurkar A; Patel V; Kshirsagar S; Sutariya B; Patel M; Patel H; Patel PR
Eur J Pharmacol; 2019 Jan; 843():113-120. PubMed ID: 30458168
[TBL] [Abstract][Full Text] [Related]
56. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.
Xie D; Wang J; Wu X; Li M
Int Urol Nephrol; 2018 Dec; 50(12):2201-2206. PubMed ID: 30073615
[TBL] [Abstract][Full Text] [Related]
57. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.
Joharapurkar AA; Patel VJ; Kshirsagar SG; Patel MS; Savsani HH; Jain MR
Drug Dev Res; 2021 Sep; 82(6):852-860. PubMed ID: 33480036
[TBL] [Abstract][Full Text] [Related]
58. Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers.
Olson E; Mahar KM; Morgan L; Fillmore C; Holland C; Lavery L
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):765-778. PubMed ID: 30720931
[TBL] [Abstract][Full Text] [Related]
59. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
60. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
